(Q38018841)

27 August 2017

title

Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside (English)

1 reference

27 August 2017

Feng Zhang

1

1 reference

27 August 2017

Desong Kong

series ordinal

2

1 reference

27 August 2017

Yin Lu

series ordinal

3

1 reference

27 August 2017

Shizhong Zheng

series ordinal

4

1 reference

27 August 2017

publication date

15 June 2012

1 reference

Cellular and Molecular Life Sciences

27 August 2017

published in

1 reference

27 August 2017

volume

70

1 reference

27 August 2017

issue

2

1 reference

27 August 2017

page(s)

259-276

1 reference

https://scigraph.springernature.com/pub.10.1007/s00018-012-1046-x

27 August 2017

exact match

0 references

cites work

Pathogenesis of liver fibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

The global impact of hepatic fibrosis and end-stage liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Fibrogenesis in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Transcriptional regulation of hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Nuclear receptors in liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Epigenetic codes of PPARγ in metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

PPARs and the complex journey to obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Structural basis for the activation of PPARgamma by oxidized fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Nuclear receptors versus inflammation: mechanisms of transrepression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Peroxisome proliferator-activated receptor-gamma regulates the expression of alveolar macrophage macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

The role of the amino-terminal domain in the interaction of unliganded peroxisome proliferator-activated receptor gamma-2 with nuclear receptor co-repressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

PPAR gamma and human metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

PPARγ Activation Primes Human Monocytes into Alternative M2 Macrophages with Anti-inflammatory Properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Nuclear receptor expression links the circadian clock to metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Peroxisome proliferator-activated receptors and hepatic stellate cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Peroxisome proliferator-activated receptor gamma suppresses proximal alpha1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Vitamin A and lipid metabolism: relationship between hepatic stellate cells (HSCs) and adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Gene expression profiles during hepatic stellate cell activation in culture and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Adipogenic transcriptional regulation of hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Hepatic stellate cell line modulates lipogenic transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Albumin mediates PPAR-gamma or C/EBP-alpha-induced phenotypic changes in pancreatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Fat paradox in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Absence of hepatic stellate cell retinoid lipid droplets does not enhance hepatic fibrosis but decreases hepatic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

The Necdin-Wnt Pathway Causes Epigenetic Peroxisome Proliferator-activated Receptor γ Repression in Hepatic Stellate Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Hepatic stellate cell-derived delta-like homolog 1 (DLK1) protein in liver regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Transcriptional control of the pref-1 gene in 3T3-L1 adipocyte differentiation. Sequence requirement for differentiation-dependent suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

RNA-binding protein RBMS3 is expressed in activated hepatic stellate cells and liver fibrosis and increases expression of transcription factor Prx1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Regulation of alpha1(I) collagen messenger RNA decay by interactions with alphaCP at the 3'-untranslated region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor γ in hepatic stellate cells for their antifibrotic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

PPARgamma is essential for protection against nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Troglitazone (Rezulin) and hepatic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Additive inhibitory effect of experimentally induced hepatic cirrhosis by agonists of peroxisome proliferator activator receptor gamma and retinoic acid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Protective effect of pioglitazone against endotoxin-induced liver injury through prevention of Kupffer cell sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Selective inhibition of activated stellate cells and protection from carbon tetrachloride-induced liver injury in rats by a new PPARgamma agonist KR62776.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Effectiveness of the PPARγ agonist, GW570, in liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Epidemiology and natural history of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Human fatty liver disease: old questions and new insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Oxidative and nitrosative stress and fibrogenic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Hepatology may have problems with putative surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Genomics and proteomics in liver fibrosis and cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Application of metabonomics on an experimental model of fibrosis and cirrhosis induced by thioacetamide in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Upregulation of peroxisome proliferator-activated receptor gamma coactivator gene (PGC1A) during weight loss is related to insulin sensitivity but not to energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

The safety of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Rosiglitazone: a European regulatory perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Regulatory action on rosiglitazone by the U.S. Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Second-generation thiazolidinediones and hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Roles of PPARs in NAFLD: potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1046-X

Peroxisome proliferated-activated receptor gamma ligand, Pioglitazone, does not prevent hepatic fibrosis in mice

21 January 2018

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats

1 reference

12 December 2020

The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, l-amino acid-defined diet

1 reference

12 December 2020

Chemokines in Liver Inflammation and Fibrosis

1 reference

12 December 2020

Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma.

1 reference

12 December 2020

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

1 reference

12 December 2020

Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease

1 reference

12 December 2020

Vitamin A storage in hepatic stellate cells in the regenerating rat liver: with special reference to zonal heterogeneity

1 reference

12 December 2020

Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis

1 reference

12 December 2020

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

1 reference

12 December 2020

PPARgamma ligand 15-deoxy-delta 12,14-prostaglandin J2 sensitizes human colon carcinoma cells to TWEAK-induced apoptosis

1 reference

12 December 2020

Targeted delivery of drugs for liver fibrosis

1 reference

12 December 2020

PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression

1 reference

12 December 2020

Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease

1 reference

12 December 2020

Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans

1 reference

12 December 2020

Inhibition of PPARγ prevents type I diabetic bone marrow adiposity but not bone loss

1 reference

12 December 2020

Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha

1 reference

12 December 2020

Effects of PPARg agonist pioglitazone on rat hepatic fibrosis

1 reference

12 December 2020

Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis

1 reference

12 December 2020

Peroxisome Proliferator-Activated Receptor α Protects against Obesity-Induced Hepatic Inflammation

1 reference

12 December 2020

The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement

1 reference

12 December 2020

Liver fibrogenesis and metabolic factors

1 reference

12 December 2020

Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice

1 reference

12 December 2020

Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells

1 reference

12 December 2020

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial

1 reference

12 December 2020

10.1007/S00018-012-1046-X

Identifiers

DOI

1 reference

27 August 2017

1 reference